Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Assets: 2016-2024

Historic Non-Current Assets for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $149.5 million.

  • Rocket Pharmaceuticals' Non-Current Assets fell 7.62% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.4 million, marking a year-over-year decrease of 7.62%. This contributed to the annual value of $149.5 million for FY2024, which is 20.52% down from last year.
  • As of FY2024, Rocket Pharmaceuticals' Non-Current Assets stood at $149.5 million, which was down 20.52% from $188.1 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Non-Current Assets peaked at $188.1 million during FY2023, and registered a low of $103.5 million during FY2020.
  • For the 3-year period, Rocket Pharmaceuticals' Non-Current Assets averaged around $175.1 million, with its median value being $187.7 million (2022).
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 78.87% in 2022, then decreased by 20.52% in 2024.
  • Rocket Pharmaceuticals' Non-Current Assets (Yearly) stood at $103.5 million in 2020, then climbed by 1.43% to $105.0 million in 2021, then surged by 78.87% to $187.7 million in 2022, then grew by 0.20% to $188.1 million in 2023, then dropped by 20.52% to $149.5 million in 2024.